ライフサイエンスコーパス: sleep apnoea

1 p with cardiopulmonary instability caused by sleep apnoea.

2 LVEF </=45%) treated for predominant central sleep apnoea.

3 arely developed specifically for obstructive sleep apnoea.

4 M, hypertension, angina, MI, and obstructive sleep apnoea.

5 or abnormal sleep behaviours and obstructive sleep apnoea.

6 c syndrome, type 2 diabetes, and obstructive sleep apnoea.

7 r airway motor disorders such as obstructive sleep apnoea.

8 infant death syndrome (SIDS) and obstructive sleep apnoea.

9 ced respiratory chemosensitivity and central sleep apnoea.

10 ion is impaired in patients with obstructive sleep apnoea.

11 ng hypertension in patients with obstructive sleep apnoea.

12 jor clinical problem of cyclical obstructive sleep apnoea.

13 echanism linking hypertension to obstructive sleep apnoea.

14 al neurostimulation in patients with central sleep apnoea.

15 ascular disease in patients with obstructive sleep apnoea.

16 a promising therapeutic approach for central sleep apnoea.

17 es, baseline blood pressure, and severity of sleep apnoea.

18 s widely used as a treatment for obstructive sleep apnoea.

19 MI, 0.28 (95% CI 0.10-0.74); and obstructive sleep apnoea, 0.55 (95% CI 0.40-0.87).

20 intermittent hypoxia (CIH) is a hallmark of sleep apnoea, a condition associated with diverse clinic

21 Obstructive sleep apnoea, a syndrome that leads to recurrent intermi

22 The assessment of how obstructive sleep apnoea affects cognition depends on the specificit

23 cal disorders, including cerebral ischaemia, sleep apnoea, Alzheimer's disease, multiple sclerosis, a

24 Thirteen participants with sleep apnoea and 13 controls completed two trials.

25 ia as a consequence of increased obstructive sleep apnoea and cardiovascular disease.

26 ittent hypoxia (CIH) occurs in patients with sleep apnoea and has adverse effects on multiple physiol

27 st, e.g. essential hypertension, obstructive sleep apnoea and heart failure.

28 bsence of RTN neurons probably underlies the sleep apnoea and lack of chemoreflex that characterize c

29 ion, but the association between obstructive sleep apnoea and myocardial infarction, stroke, and cong

30 specific physiological sleep disorders--eg, sleep apnoea and periodic limb movement disorder--are es

31 focus on the association between obstructive sleep apnoea and stroke reviewing both the epidemiologic

32 exity of the association between obstructive sleep apnoea and the brain.

33 Obstructive sleep apnoea and type 2 diabetes are common medical diso

34 arction (MI), stroke, fractures, obstructive sleep apnoea, and cancer; mortality; and resolution of h

35 cal phenotypes including ptosis, obstructive sleep apnoea, and the occurrence of seizures.

36 leep-related disorders including obstructive sleep apnoea (apnea), REM sleep behaviour disorder (RBD)

37 CIH and sleep apnoea are characterized by increased reactive oxy

38 eep movements and behaviours and obstructive sleep apnoea, as confirmed by polysomnography.

39 Obstructive sleep apnoea can be diagnosed on the basis of characteri

40 Obstructive sleep apnoea causes sleepiness, road traffic accidents,

41 insufficiency in diverse conditions, such as sleep apnoea, cervical spinal injury or amyotrophic late

42 l trial of therapeutic NCPAP for obstructive sleep apnoea compared with a control group on subtherape

43 ause brain hypoperfusion such as obstructive sleep apnoea, congestive heart failure, cardiac arrhythm

44 p-deprived normal subjects and patients with sleep apnoea could react differently.

45 olic abnormalities in those with obstructive sleep apnoea could reduce cardiovascular disease risk an

46 will be discussed, management of obstructive sleep apnoea could soon transition from a so-called one

47 Men with obstructive sleep apnoea, defined as an Epworth sleepiness score of

48 Dips suggestive of obstructive sleep apnoea did not predict CNS events, and adenotonsil

49 n blood pressure in 118 men with obstructive sleep apnoea (Epworth score > 9, and a > 4% oxygen desat

50 Patients with obstructive sleep apnoea experience chronic intermittent hypoxia-hyp

51 r related pathologies, including obstructive sleep apnoea, heart failure and diabetes.

52 Obstructive sleep apnoea/hypopnoea syndrome, depression and anxiety

53 in 24.5% (13/53); five of these patients had sleep apnoea/hypopnoea syndrome, six had depression and

54 tivity observed in patients with obstructive sleep apnoea (i.e. reflex compensation for an anatomical

55 cause of perinatal mortality in infants and sleep apnoea in adults, but the mechanisms of respirator

56 pearance of OSA and the emergence of central sleep apnoea in conditions such as high altitude.

57 Early identification of obstructive sleep apnoea in patients with metabolic dysfunction, inc

58 red respiratory chemosensitivity and central sleep apnoea in this disorder.

59 ignificantly reduced the severity of central sleep apnoea, including improvements in sleep metrics, a

60 Obstructive sleep apnoea is a common disease that is now more widely

61 Obstructive sleep apnoea is a disease of increasing importance becau

62 There is convincing evidence to believe that sleep apnoea is a modifiable risk factor for stroke; how

63 Central sleep apnoea is a serious breathing disorder associated

64 Obstructive sleep apnoea is an increasingly common disorder of repea

65 Obstructive sleep apnoea is associated with raised blood pressure.

66 A co-morbidity of sleep apnoea is hypertension associated with elevated sy

67 r control and thus could explain why central sleep apnoea is less frequent in REM sleep.

68 primary sleep disorders such as obstructive sleep apnoea may worsen epilepsy and treatment of these

69 In patients with most severe sleep apnoea, nCPAP reduces blood pressure, providing si

70 h of more than 4% SaO2 caused by obstructive sleep apnoea on overnight sleep study, were randomly ass

71 Obstructive sleep apnoea (OSA) and type 2 diabetes frequently co-exi

72 roup of elderly individuals with obstructive sleep apnoea (OSA) for comparison (n = 3, age 68 +/- 1 y

73 ther PA and vLTF are enhanced in obstructive sleep apnoea (OSA) participants compared to matched heal

74 re (CPAP) for moderate to severe obstructive sleep apnoea (OSA) syndrome have been established in mid

75 od O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhibit a heighte

76 od O2 saturation profiles during obstructive sleep apnoea (OSA), have been shown to exhibit a heighte

77 ation (SF), a primary feature of obstructive sleep apnoea (OSA), impairs hippocampal long-term potent

78 Obstructive sleep apnoea (OSA), which is characterized by periodic i

79 loop gain (LG) in patients with obstructive sleep apnoea (OSA), yet its effects on the other traits

80 a relatively high prevalence of obstructive sleep apnoea (OSA).

81 a relatively high prevalence of obstructive sleep apnoea (OSA).

82 return to sleep in patients with obstructive sleep apnoea (OSA).

83 t that acetazolamide may improve obstructive sleep apnoea (OSA).However, how acetazolamide affects th

84 who demonstrated spontaneous apnoeas during sleep, apnoea per se did not alter burst latency relativ

85 rate progression of, obstructive and central sleep apnoea, possibly through the development of periph

86 rm 36 mental component summary (MCS) and the sleep apnoea quality-of-life index symptoms domain (sym)

87 Our aim was to see whether nCPAP for sleep apnoea reduces blood pressure compared with the mo

88 ure, the treatment of choice for obstructive sleep apnoea, reduces sleepiness and improves hypertensi

89 lysomnography showed features of obstructive sleep apnoea, stridor, and abnormal sleep architecture (

90 ortant in the pathophysiology of obstructive sleep apnoea syndrome (OSA).

91 ortant in the pathophysiology of obstructive sleep apnoea syndrome (OSA).

92 ntribution of genetic factors to obstructive sleep apnoea syndrome (OSAS) has led to a better underst

93 seven healthy humans and three patients with sleep apnoea syndrome during NREM sleep.

94 onalcoholic fatty liver disease, obstructive sleep apnoea syndrome, erectile dysfunction, periodontit

95 important in the pathogenesis of obstructive sleep apnoea syndrome.

96 efit was larger in patients with more severe sleep apnoea than those who had less severe apnoea, but

97 past two decades indicates that obstructive sleep apnoea, through the effects of intermittent hypoxa

98 usitis, gastroesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction, obesity, dysfuncti

99 he pathogenesis and treatment of obstructive sleep apnoea, we have developed a novel application of m

100 Many patients with stroke have concomitant sleep apnoea, which can affect recovery potential.

101 upon such mechanisms (as in the patient with sleep apnoea) will be prone to collapse during sleep.

102 (SERVE-HF) showed that treatment of central sleep apnoea with adaptive servoventilation in patients

103 cent insights and discoveries in obstructive sleep apnoea, with a focus on diagnostics and therapeuti